- Home
- BBU vs TNGX Comparison
BBU vs TNGX Comparison
Compare BBU & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBU | TNGX |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.7B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BBU | TNGX |
|---|---|---|
| Price | $31.46 | $21.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $39.40 | $21.78 |
| AVG Volume (30 Days) | 149.9K | ★ 2.8M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $21.07 | $1.04 |
| 52 Week High | $37.75 | $28.41 |
Technical Indicators
Market Signals| Indicator | BBU | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 45.80 |
| Support Level | $29.90 | $6.83 |
| Resistance Level | $36.93 | $22.01 |
| Average True Range (ATR) | 1.38 | 1.87 |
| MACD | 0.23 | -0.60 |
| Stochastic Oscillator | 46.92 | 17.19 |
Price Performance
Historical ComparisonAbout BBU Brookfield Business Partners L.P. Limited Partnership Units
Brookfield Business Partners LP is a business services and industrials company. It focused on operating businesses that are either low-cost producers and benefit from high barriers to entry. The company's operating segment includes Business services; Infrastructure services; Industrials and Corporate and other. It generates maximum revenue from the Business Services segment. Geographically operates in USA, Europe, Australia, Brazil, Canada, UK, Mexico and Other, majority of revenue is from UK.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.